Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 3, 2009
Event: Regulation FD Disclosure regarding the acquisition of Denville Scientific, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a corporate event rather than a financial statement.
Material Changes
- Acquisition: On September 3, 2009, Harvard Bioscience, Inc. announced the acquisition of Denville Scientific, Inc.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) containing details of the acquisition but does not include specific guidance, outlook, or risk factors within the body of this 8-K text.
Legal Disclaimer: The information in this report and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific terms of the Denville Scientific, Inc. acquisition.
- Verify the financial impact and integration strategy of the acquisition in subsequent filings (e.g., 10-Q or 10-K).
- Confirm the regulatory status of the transaction and any required shareholder approvals.